Central to this classification are molecular markers, notably the isocitrate dehydrogenase (IDH) and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutations, which have emerged as pivotal elements in characterizing gliomas and informing clinical decision making [1,7,8]. The gene discussed is IDH1; the disease is central nervous system cancer.